Oryzon Genomics SA ORY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
-
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
-
ORYZON to Participate in Upcoming Events in September and October
-
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
-
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
Trading Information
- Previous Close Price
- €2.58
- Day Range
- €2.55–2.61
- 52-Week Range
- €2.48–3.75
- Bid/Ask
- €2.56 / €2.61
- Shares Outstanding
- 81.96M
- Market Cap
- €213.25M
- Volume/Avg
- 90,954 / 183,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.01%
Company Profile
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 44
- Website
- http://www.oryzon.com
Valuation
|
Metric
|
ORY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ORY
|
|---|---|
Quick Ratio | 1.59 |
Current Ratio | 1.60 |
Interest Coverage | — |
Quick Ratio
ORY
Profitability
|
Metric
|
ORY
|
|---|---|
Return on Assets (Normalized) | −1.45% |
Return on Equity (Normalized) | −1.76% |
Return on Invested Capital (Normalized) | −2.75% |
Return on Assets
ORY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sw$f$j | LOCK|j>ll | $133B | |||
| Moderna Inc
MRNA
| LOCK|w$Lm>s | LOCK|q# | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<@Mj%R% | LOCK|fZn> | $83B | |||
| argenx SE ADR
ARGX
| LOCK|W#b?>p< | LOCK|<^p | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^gt!Y^! | LOCK|@Q | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>xxQ@WM | LOCK|&V@Ww | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|M<%%c^F | LOCK|%t?Y | $28B | |||
| Incyte Corp
INCY
| LOCK|@>gdxwW | LOCK|cbZ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|YN>@wr | LOCK|$f | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Z^y!VSf | LOCK|CW | $14B |
United States